On July 29, 2024, the U.S. FDA approved Alpha Cognition Inc.'s ALPHA-1062 (Zunveyl ®), an Acetylcholinesterase (AChE) inhibitor, for treating mild-to-moderate Alzheimer’s disease. This condition ...
Researchers have identified a new mechanism that underlies dopamine release in the brain. The research, conducted in mice, shows that another chemical messenger called acetylcholine can trigger the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback